(Q40620716)

22 September 2017

1 reference

title

Salmeterol: a novel, long-acting beta 2-agonist (English)

1 reference

22 September 2017

J M Meyer

1

1 reference

22 September 2017

C L Wenzel

series ordinal

2

1 reference

22 September 2017

W A Kradjan

series ordinal

3

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 December 1993

1 reference

Annals of Pharmacotherapy

22 September 2017

published in

1 reference

22 September 2017

volume

27

1 reference

22 September 2017

issue

12

1 reference

22 September 2017

page(s)

1478-1487

1 reference

Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta- adrenoceptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Approaches to a long-acting, selective beta 2-adrenoceptor stimulant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Prevention of exercise induced asthma by inhaled salmeterol xinafoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Effect of sustained release terbutaline on symptoms and sleep quality in patients with nocturnal asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Dose-response study with high-dose inhaled salmeterol in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potassium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Pharmacologic management of obstructive lung disease. Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Regular inhaled beta-agonist treatment in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

A comparison of the effect of salmeterol and salbutamol in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809302701214

10.1177/106002809302701214

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference